Table 2. Comparison With Previous Studies.
| Study characteristic | Satukijchai et al | Jurynczyk et al, 201711 | Cobo-Calvo et al, 201823 | Cobo-Calvo et al, 202110 | Jarius et al, 201619 | Pandit et al, 201824 | Cobo-Calvo et al, 20199 | Senanayaka et al, 201912 | Ramanathan et al, 201820 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cohort | Incident group | Total cohort | Incident group | Total cohort | Incident group | |||||||
| Country | UK | UK | UK | UK (Oxford) | France | France | France | German | India | France and Spain | Sri Lanka | Australia and New Zealand |
| Center | Multicenter | Multicenter | Multicenter | Single center | Multicenter | Multicenter | Multicenter | Multicenter | Single center | Multicenter | Multicenter | Multicenter |
| Patients, No. | 276 | 204 | 252 | 44 | 197 | 139 | 366 | 50 | 42 | 125 | 126 | 59 |
| Female patients (%) | 60.3 | 57.6 | 57.0 | 48.0 | 49.2 | 47.48 | 51.0 | 74.0 | 42.9 | 55.2 | 56.0 | 67.8 |
| Age at onset, median (range), y | 25 (1-72) | 28 (1-72) | Mean (SD), 30.1 (18.3) | Mean (SD), 32.0 (17.6) | 36.5 (19.0-76.8) | 37.4 (18.9-76.7) | 29.9 (16.7-41.7) | 31 (6-70) | 21 (6-53) | 34.1 (18.0-67.1) | 26 (3-68) | 12 (1-74) |
| Children (No.) | 114 (≤18 y) | 68 (≤18 y) | 81 (≤16 y) | NA | All adult | All adult | 98 (<18 y) | 8 (<18 y) | 13 (<18 y) | All adult | 44 (<18 y) | 33 (≤16 y) |
| Predominate racial or ethnic group (%) | White (79.7) | White (71.7) | White (78.2) | NA | White (92.9) | White (91.4) | NA | White (98.0) | Asian (100) | White (96.0) | Sinhalese (85.0) | White (72.9) |
| Disease duration, median (range), mo | 36.0 (1.2-540.0) | 24.0 (1.2-235.1) | 26.0 (0-492.0) | 15.5 (1.0-57.0) | 15.8 (1.0-556.0) FU duration | 10.8 (1.0-37.0) FU duration | 36.0 (6.0-637.0) | Monophasic: 26.0 mo; relapsing: 52.5 mo FU duration | 57.6 (12.0-336.0) | 54.0 (2.4-564.0) FU duration | 48.0 (1.4-240.0) FU duration | 45.0 (12.0-288.0) FU duration |
| Disease course (% relapsing) | 50.4 | 37.1 | 44.0 | 36.0 | 42.1 | 26.6 | 55.2 | 80.0 | 57.1 | Only relapse | 34.0 | Only relapse |
| ARR, mean (SD) | 0.59 (0.45) | 0.66 (0.52) | 0.2 (Oxford incident group) | NA | 0.37 (0.79) | 0.38 (0.92) | 0.23 (0.35) | Median (range), 0.83 (0.05-6.92) | 1.04 (0.03) | 0.79 (0.91) | NA | NA |
| Onset phenotype (%) | ON (43.3) | ON (41.5) | Unilateral ON (31.0) | Unilateral ON (18.0) | ON (60.9) | ON (64.1) | ON (40.8) | ON (64.0) | ON (40.5) | ON (65.6) | ON (51.0) | ON (54.0) |
| Bilateral ON (24.0) | Bilateral ON (27.0) | |||||||||||
| TM (18.5) | TM (20.2) | TM (18.0) | TM (21.0) | TM (22.3) | TM (17.9) | TM (12.2) | TM (18.0) | TM (52.4) | TM (20.0) | TM (23.0) | ADEM (20.0) | |
| ON with TM (8.7) | ON with TM (9.8) | ON with TM (9.0) | ON with TM (9.0) | ON with TM (7.6) | ON with TM (8.6) | ON with TM (4.1) | ON with TM (10.0) | BS (2.4) | ON with TM (7.2) | ON with TM (6.0) | Other (26.0) | |
| ADEM, brain, BS (29.5) | ADEM, brain, BS (28.5) | ADEM, ADEM-like (18.0) | ADEM, ADEM-like (25.0) | BS (4.0) | BS (2.9) | ADEM (36.7) | BS (2.0) | Encephalitis (4.7) | BS with encephalitis (7.2) | ADEM (9.0) | NA | |
| BS with encephalitis (2.0) | BS with encephalitis (2.2) | |||||||||||
| NA | NA | NA | NA | BS with ON (0.5) | BS with ON (0.7) | BS (6.1) | Encephalitis with myelitis (6.0) | NA | NA | ON with intractable hiccup (1.0) | NA | |
| Encephalitis (2.5) | Encephalitis (3.6) | |||||||||||
| NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ON with ADEM (10.0) | NA | |
| MOG assay | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live CBA a1 | Live Flow a1 | Live flow a1 |
| MOG construct secondary Ab | MOG IgG1 | MOG IgG1 | MOG IgG1 | MOG IgG1 | MOG-GFP IgG | MOG-GFP IgG | MOG-GFP IgG | MOG-GFP IgG | MOG IgG | MOG IgG | MOG IgG1 | MOG-GFP IgG |
Abbreviations: Ab, antibody; ADEM, acute disseminated encephalomyelitis; BS, brain stem; CBA, cell-based assay; FU duration, follow-up duration; GFP, green fluorescent protein; NA, not applicable; ON, optic neuritis; ON with TM, simultaneous optic neuritis with transverse myelitis; TM, transverse myelitis.